BACKGROUND: Motesanib is a potent inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, platelet-derived growth factor receptor, and Kit receptors. In this report we examine the interaction between motesanib and radiation in vitro and in head and neck squamous cell carcinoma (HNSCC) xenograft models. EXPERIMENTAL DESIGN: In vitro assays were done to assess the impact of motesanib on VEGFR2 signaling pathways in human umbilical vein endothelial cells (HUVEC). HNSCC lines grown as tumor xenografts in athymic nude mice were utilized to assess the in vivo activity of motesanib alone and in combination with radiation. RESULTS: Motesanib inhibited VEGF-stimulated HUVEC proliferation in vitro, as well as VEGFR2 kinase activity. Additionally, motesanib and fractionated radiation showed additive inhibitory effects on HUVEC proliferation. In vivo combination therapy with motesanib and radiation showed increased response compared with drug or radiation alone in UM-SCC1 (P < 0.002) and SCC-1483 xenografts (P = 0.001); however, the combination was not significantly more efficacious than radiation alone in UM-SCC6 xenografts. Xenografts treated with motesanib showed a reduction of vessel penetration into tumor parenchyma, compared with control tumors. Furthermore, triple immunohistochemical staining for vasculature, proliferation, and hypoxia showed well-defined spatial relationships among these parameters in HNSCC xenografts. Motesanib significantly enhanced intratumoral hypoxia in the presence and absence of fractionated radiation. CONCLUSIONS: These studies identify a favorable interaction when combining radiation and motesanib in HNSCC models. The data presented suggest that motesanib reduces blood vessel penetration into tumors and thereby increases intratumoral hypoxia. These findings suggest that clinical investigations examining combinations of radiation and motesanib are warranted in HNSCC. Copyright 2010 AACR.
BACKGROUND:Motesanib is a potent inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, platelet-derived growth factor receptor, and Kit receptors. In this report we examine the interaction between motesanib and radiation in vitro and in head and neck squamous cell carcinoma (HNSCC) xenograft models. EXPERIMENTAL DESIGN: In vitro assays were done to assess the impact of motesanib on VEGFR2 signaling pathways in human umbilical vein endothelial cells (HUVEC). HNSCC lines grown as tumor xenografts in athymic nude mice were utilized to assess the in vivo activity of motesanib alone and in combination with radiation. RESULTS:Motesanib inhibited VEGF-stimulated HUVEC proliferation in vitro, as well as VEGFR2 kinase activity. Additionally, motesanib and fractionated radiation showed additive inhibitory effects on HUVEC proliferation. In vivo combination therapy with motesanib and radiation showed increased response compared with drug or radiation alone in UM-SCC1 (P < 0.002) and SCC-1483 xenografts (P = 0.001); however, the combination was not significantly more efficacious than radiation alone in UM-SCC6 xenografts. Xenografts treated with motesanib showed a reduction of vessel penetration into tumor parenchyma, compared with control tumors. Furthermore, triple immunohistochemical staining for vasculature, proliferation, and hypoxia showed well-defined spatial relationships among these parameters in HNSCC xenografts. Motesanib significantly enhanced intratumoral hypoxia in the presence and absence of fractionated radiation. CONCLUSIONS: These studies identify a favorable interaction when combining radiation and motesanib in HNSCC models. The data presented suggest that motesanib reduces blood vessel penetration into tumors and thereby increases intratumoral hypoxia. These findings suggest that clinical investigations examining combinations of radiation and motesanib are warranted in HNSCC. Copyright 2010 AACR.
Authors: Anthony Polverino; Angela Coxon; Charlie Starnes; Zobedia Diaz; Thomas DeMelfi; Ling Wang; James Bready; Juan Estrada; Russell Cattley; Stephen Kaufman; Danlin Chen; Yongmei Gan; Gondi Kumar; James Meyer; Sesha Neervannan; Gonzalo Alva; Jane Talvenheimo; Silvia Montestruque; Andrew Tasker; Vinod Patel; Robert Radinsky; Richard Kendall Journal: Cancer Res Date: 2006-09-01 Impact factor: 12.701
Authors: Gary M Tse; Anthony W H Chan; Kwok-Hung Yu; Ann D King; Ka-Tak Wong; George G Chen; Raymond K Y Tsang; Amy B W Chan Journal: Ann Surg Oncol Date: 2007-10-11 Impact factor: 5.344
Authors: Steven I Sherman; Lori J Wirth; Jean-Pierre Droz; Michael Hofmann; Lars Bastholt; Renato G Martins; Lisa Licitra; Michael J Eschenberg; Yu-Nien Sun; Todd Juan; Daniel E Stepan; Martin J Schlumberger Journal: N Engl J Med Date: 2008-07-03 Impact factor: 91.245
Authors: Lee S Rosen; Razelle Kurzrock; Marilyn Mulay; Andy Van Vugt; Michelle Purdom; Chaan Ng; Jeffrey Silverman; Antonis Koutsoukos; Yu-Nien Sun; Michael B Bass; Ren Y Xu; Anthony Polverino; Jeffrey S Wiezorek; David D Chang; Robert Benjamin; Roy S Herbst Journal: J Clin Oncol Date: 2007-06-10 Impact factor: 44.544
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245
Authors: Angela Coxon; Tammy Bush; Douglas Saffran; Stephen Kaufman; Brian Belmontes; Karen Rex; Paul Hughes; Sean Caenepeel; James B Rottman; Andrew Tasker; Vinod Patel; Richard Kendall; Robert Radinsky; Anthony Polverino Journal: Clin Cancer Res Date: 2009-01-01 Impact factor: 12.531
Authors: Matthew J Nyflot; Tim J Kruser; Anne M Traynor; Deepak Khuntia; David T Yang; Gregory K Hartig; Timothy M McCulloch; Peggy A Wiederholt; Lindell R Gentry; Tien Hoang; Robert Jeraj; Paul M Harari Journal: Int J Radiat Oncol Biol Phys Date: 2015-02-03 Impact factor: 7.038